CDMO Expansion Will Widen Global Cell And Gene Therapy Access

Key Takeaways

• Expansion into AAV and other vector types reduces dependency risks and supports earnings growth through diversified revenue streams.
  
• Strategic initiatives and expanded operations within the cell and gene therapy market drive revenue growth and enhance market share opportunities.
  
• Increased capital and operational costs from manufacturing expansion, geopolitical tariffs, and exchange rate fluctuations threaten revenue growth and profitability if market conditions worsen.

Catalysts

A contract development and manufacturing organization, focuses on delivering therapies to patients worldwide.

• Oxford Biomedica's 'One OXB' initiative, which has expanded their global operational footprint, enables them to access 75% of the cell and gene therapy market. This will likely drive revenue growth as the company captures programs across the U.S., U.K., and Continental Europe.
  
• The increasing demand for their differentiated CDMO services, highlighted by a 35% rise in contracted client orders, positions OXB for sustained growth and an increase in overall revenue.
  
• Their development and manufacturing capabilities expansion into AAV and other vector types diversify their revenue streams, reducing dependency on any single vector type and potentially enhancing overall earnings and EBITDA margins.
  
• The forecast CAGR of approximately 20% for the broader cell and gene therapy market through to 2030 presents a favorable industry backdrop. As OXB is well-positioned to benefit from this growth, this is expected to positively impact their revenue and market share.
  
• Their successful reduction in operating expenses and expectation of achieving EBITDA profitability by 2025, combined with the already covered 80% revenue guidance for that year, indicates potential for improved net margins and earnings stability.

Oxford Biomedica Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

• Analysts are assuming Oxford Biomedica's revenue will grow by 26.3% annually over the next 3 years.
• Analysts assume that profit margins will increase from -17.9% today to 14.3% in 3 years time.
• Analysts expect earnings to reach £48.5 million (and earnings per share of £0.39) by about June 2029, up from -£30.1 million today.
• In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 32.0x on those 2029 earnings, up from -24.1x today. This future PE is greater than the current PE for the GB Biotechs industry at 19.2x.
• Analysts expect the number of shares outstanding to grow by 7.0% per year for the next 3 years.
• To value all of this in today's terms, we will use a discount rate of 7.72%, as per the Simply Wall St company report.

Risks

• Potential exposure to tariffs given the geopolitical climate could affect operational costs and supply chain efficiencies, impacting net margins and earnings.
  
• Client program failures common in clinical development could slow revenue growth and affect the transition of clients from clinical to commercial stages, impacting revenue projections.
  
• Currency exchange rate fluctuations can introduce unpredictability into financial outcomes, affecting revenue and potentially net earnings due to the multi-currency revenue and cost structure.
  
• Dependence on expanding manufacturing capacity in the U.S. and Europe could lead to increased capital expenditure and operational costs, impacting net margins if not properly managed.
  
• High reliance on continued market demand and the clinical success of client programs poses risk; downturns in the biotech sector or slowdown in client orders could impact revenue and profitability.

Valuation

How have all the factors above been brought together to estimate a fair value?

• The analysts have a consensus price target of £8.41 for Oxford Biomedica based on their expectations of its future earnings growth, profit margins and other risk factors.
• However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of £11.7, and the most bearish reporting a price target of just £5.5.
• In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be £340.2 million, earnings will come to £48.5 million, and it would be trading on a PE ratio of 32.0x, assuming you use a discount rate of 7.7%.
• Given the current share price of £6.0, the analyst price target of £8.41 is 28.6% higher.
• We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.